NCI’s Srivastava Wins Proteomics Award

Dr. Sudhir Srivastava

Dr. Sudhir Srivastava, chief of the cancer biomarkers research group, NCI Division of Cancer Prevention, was honored by the Human Proteome Organization (HUPO) with the 2017 Clinical and Translational Proteomics Award Sept. 20 at the group’s annual World Congress in Dublin, Ireland.

The group named Srivastava “a visionary and proactive leader who has worked with HUPO since its inception.” They cited his “tremendous commitment and leadership” to the NCI Early Detection Research Network, which he has headed from its start in 2000, and which focuses on the discovery and validation of proteomics, genomic, metabolomics, epigenomic and other “omic” markers of cancer detection and prognosis. 

In the field of proteomic biomarkers, translational research bridges the gap between basic research discoveries that identify biomolecules involved in or are the result of carcinogenesis and the clinical application of these discoveries.